Brief: Coya Therapeutics Inc Says Expansion Of Its Patent Estate For COYA 301, Company's Low-Dose IL-2 (ld IL-2) Subcutaneous Administration Product Candidate
20/06/2023 12:13
June 20 (Reuters) - Coya Therapeutics Inc COYA.O :
* COYA THERAPEUTICS INC - EXPANSION OF ITS PATENT ESTATE FOR
COYA
301, COMPANY'S LOW-DOSE IL-2 (LD IL-2) SUBCUTANEOUS
ADMINISTRATION PRODUCT CANDIDATE
* COYA THERAPEUTICS -UNDER TERMS OF AGREEMENT WITH UNEMED,
GRANTED
EXCLUSIVE PATENT RIGHTS & KNOW-HOW FOR USE OF LDIL-2 AND LD IL-2
COMBINATIONS FOR PD
* COYA THERAPEUTICS INC - UNEMED WILL RECEIVE PAYMENTS UPON
ACHIEVEMENT OF CERTAIN MILESTONES
* COYA THERAPEUTICS INC - UNEMED WILL ALSO BE ELIGIBLE TO
RECEIVE
TIERED LOW-SINGLE DIGIT ROYALTY ON NET SALES
Source text for Eikon: ID:nBw982y77a
Further company coverage: COYA.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Coya Therapeutics
See all newsCoya Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Coya Therapeutics Q2 net loss widens as R&D costs rise
Coya Therapeutics Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: Coya Therapeutics Entered Into Sales Agreement, May Offer And Sell From Time To Time Shares Of Co's Common Stock For Up To $30 Million
Brief: Coya Therapeutics Has Been Granted U.S. FDA Fast Track Designation For Coya 302 For The Treatment Of Amyotrophic Lateral Sclerosis (ALS)